EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Shares in PharmaMar crashed after the Spanish biotech revealed a phase 3 ovarian cancer trial had missed its primary endpoint. Synthetic tetrahydroisoquinoline alkaloid Zepsyre failed to improve progression-free survival in patients with platinum-resistant ovarian cancer. Statement (PDF)

> Ablynx named Robert Friesen, Ph.D., as its CSO. Friesen joins from ProQR at a time when Ablynx is the subject of takeover interest from Novo Nordisk. Release

> BioCanCell unveiled plans to list its stock in the U.S. The Israeli biotech revealed its IPO intentions in a statement about the pricing of a $25 million (€20 million) financing round. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Advicenne followed up on its IPO by appointing Linda Law, M.D., to oversee its U.S. clinical trial activities. Release

> Genfit kicked off its pediatric NASH program. Statement

> ImmuPharma raised £10 million ($14 million). Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.